What is the Krystal Biotech Inc. stock price forecast?

Krystal Biotech Inc. is currently trading at $317.97. View real-time AI analysis on Alpha Lenz.

What is Krystal Biotech Inc. insider trading activity?

View the latest insider trading data for Krystal Biotech Inc. on Alpha Lenz.

What is Krystal Biotech Inc.'s P/E ratio?

Krystal Biotech Inc.'s P/E ratio is 44.9.

Krystal Biotech Inc.

NASDAQ · KRYS

$317.97-3.57(-1.11%)Pre-market

Ask about Krystal Biotech Inc.'s future dividend policy...

Alpha Chat Insight

“Krystal Biotech Inc. trades at a P/E of 44.9 (premium valuation) with strong ROE of 18.9%. Operating margin of 41.5% indicates strong profitability.”

Ask for details →

Company Overview

Krystal Biotech Inc. is a biotechnology company primarily focused on developing and commercializing gene therapy products for patients with rare dermatological conditions. Its innovative platform harnesses gene delivery technology to address unmet medical needs by developing a pipeline of products aimed at treating genetic skin diseases. Krystal Biotech’s key asset is its proprietary STAR-D platform, which allows for the non-viral delivery of therapeutic genes directly into the skin. This platform exemplifies the company's commitment to deploying cutting-edge science to improve patient outcomes. The company primarily impacts the healthcare and biotechnology sectors, seeking to revolutionize treatments for genetic disorders. Incorporated in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a significant role in advancing therapeutic options within the niche market of dermatological diseases, thereby positioning itself as a transformative player in gene therapy and medical research.

CEOMr. Krish S. Krishnan M.B.A., M.S.

Websitehttps://www.krystalbio.com

SectorHealthcare

IndustryBiotechnology

Employees275

Company Statistics

FY 2025

Profile

$9.20BMarket Cap

$389.13MRevenue

0.00Shares Out

275Employees

Margins

94.08%Gross

43.13%EBITDA

41.45%Operating

48.69%Pre-Tax

52.64%Net

Valuation

44.93P/E

7.55P/B

23.65EV/Sales

51.93EV/EBITDA

48.72P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

17.14%ROA

18.91%ROE

13.50%ROIC

Financial Health

$496.30MCash & Cash Equivalents

$-382.07MNet Debt

9.37%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Krystal Biotech Inc. trades at a P/E of 44.9 (premium valuation) with strong ROE of 18.9%. Operating margin of 41.5% indicates strong profitability.”

Ask for details →

Frequently Asked Questions

Krystal Biotech Inc. (ticker: KRYS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 275 employees. Market cap is $9.2B.

The current price is $317.97 with a P/E ratio of 44.93x and P/B of 7.55x.

ROE is 18.91% and operating margin is 41.45%. Annual revenue is $389M.